Cell-Extracellular Matrix and Cell-Cell Interfaces

Cell-Extracellular Matrix and Cell-Cell Interfaces represent the physical and functional junctions where cells connect to their environment and to each other. These interfaces are composed of complex assemblies of proteins, including integrins, cadherins, selectins, and extracellular matrix (ECM) components like collagen and fibronectin, which provide structural stability and mediate essential signaling pathways (Alberts et al., Molecular Biology of the Cell). These structures are vital for maintaining tissue architecture, regulating cell growth, and facilitating the movement of immune cells through the body (Reactome, R-HSA-446728). In various disease states, these interfaces are often hijacked or dysregulated; for instance, cancer cells alter their adhesion properties to detach from primary tumors and metastasize, while chronic inflammation involves the excessive recruitment of leukocytes via these interface receptors (NCBI Bookshelf, Cell Adhesion and the ECM). Therapeutically, this 'target' is actually a broad category of molecular interactions rather than a single molecule. Modern medicine utilizes monoclonal antibodies and small molecules to target specific receptors within these interfaces, such as integrins, to treat conditions like multiple sclerosis, Crohn's disease, and acute coronary syndrome. By blocking these interactions, drugs can effectively interrupt pathological cell-cell or cell-matrix communication, although this often comes with risks such as impaired immune surveillance or bleeding (PubMed, PMID: 28842211).

Other names

Cell-matrix and cell-cell junctionsCell-adhesion interfaceECM-cell interactionsCell-to-cell and cell-to-matrix adhesion

Drugs targeting components of these interfaces typically function as competitive antagonists or monoclonal antibodies that block the binding of cell-surface receptors (such as integrins or selectins) to their respective ligands in the extracellular matrix or on the surface of other cells. This inhibition prevents cellular processes such as leukocyte recruitment to inflammatory sites, platelet aggregation, or tumor cell extravasation.